自膨胀式TAVR与外科主动脉瓣置换在中危患者中的5年结局:SURTAVI随机临床试验
SURTAVI试验在1660例中危重度主动脉瓣狭窄患者中比较自膨胀式经导管主动脉瓣置换(TAVR)与外科生物瓣置换,5年时死亡或致残性卒中率相似(31.3% vs 30.8%),TAVR瓣膜血流动力学更优但中重度瓣周漏和再干预更多。
要点
- 中危患者5年死亡或致残性卒中TAVR与外科相似(31.3% vs 30.8%)。
- TAVR跨瓣压差更低、瓣口面积更大,但中重度瓣周漏更多。
- TAVR新起搏器植入率和瓣膜再干预率高于外科。
核心结论
- 在中危症状性重度主动脉瓣狭窄患者中,TAVR与外科5年主要临床结局相似。
- TAVR瓣膜血流动力学性能更优,但瓣周漏和瓣膜再干预更多。
研究设计与样本
- SURTAVI为前瞻性随机非盲临床试验,纳入87个中心的中危重度主动脉瓣狭窄患者。
- 共1660例患者接受TAVR(n=864)或外科(n=796)手术,平均年龄79.8岁,女性43.6%,STS预测死亡风险均值4.5%。
主要发现
- 5年死亡或致残性卒中率TAVR 31.3% vs 外科30.8%(HR 1.02,95%CI 0.85-1.22;P=0.85)。
临床怎么用
- 中危重度主动脉瓣狭窄患者选择TAVR或外科时应综合评估,5年死亡或致残性卒中风险相似。
- TAVR血流动力学更优但需关注瓣周漏和起搏器植入风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients with severe aortic valve stenosis at intermediate surgical risk, transcatheter aortic valve replacement (TAVR) with a self-expanding supra-annular valve was noninferior to surgery for all-cause mortality or disabling stroke at 2 years. Comparisons of longer-term clinical and hemodynamic outcomes in these patients are limited. OBJECTIVE: To report prespecified secondary 5-year outcomes from the Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI) randomized clinical trial. DESIGN, SETTING, AND PARTICIPANTS: SURTAVI is a prospective randomized, unblinded clinical trial. Randomization was stratified by investigational site and need for revascularization determined by the local heart teams. Patients with severe aortic valve stenosis deemed to be at intermediate risk of 30-day surgical mortality were enrolled at 87 centers from June 19, 2012, to June 30, 2016, in Europe and North America. Analysis took place between August and October 2021. INTERVENTION: Patients were randomized to TAVR with a self-expanding, supra-annular transcatheter or a surgical bioprosthesis. MAIN OUTCOMES AND MEASURES: The prespecified secondary end points of death or disabling stroke and other adverse events and hemodynamic findings at 5 years. An independent clinical event committee adjudicated all serious adverse events and an independent echocardiographic core laboratory evaluated all echocardiograms at 5 years. RESULTS: A total of 1660 individuals underwent an attempted TAVR (n = 864) or surgical (n = 796) procedure. The mean (SD) age was 79.8 (6.2) years, 724 (43.6%) were female, and the mean (SD) Society of Thoracic Surgery Predicted Risk of Mortality score was 4.5% (1.6%). At 5 years, the rates of death or disabling stroke were similar (TAVR, 31.3% vs surgery, 30.8%; hazard ratio, 1.02 [95% CI, 0.85-1.22]; P = .85). Transprosthetic gradients remained lower (mean [SD], 8.6 [5.5] mm Hg vs 11.2 [6.0] mm Hg; P < .001) and aortic valve areas were higher (mean [SD], 2.2 [0.7] cm2 vs 1.8 [0.6] cm2; P < .001) with TAVR vs surgery. More patients had moderate/severe paravalvular leak with TAVR than surgery (11 [3.0%] vs 2 [0.7%]; risk difference, 2.37% [95% CI, 0.17%- 4.85%]; P = .05). New pacemaker implantation rates were higher for TAVR than surgery at 5 years (289 [39.1%] vs 94 [15.1%]; hazard ratio, 3.30 [95% CI, 2.61-4.17]; log-rank P < .001), as were valve reintervention rates (27 [3.5%] vs 11 [1.9%]; hazard ratio, 2.21 [95% CI, 1.10-4.45]; log-rank P = .02), although between 2 and 5 years only 6 patients who underwent TAVR and 7 who underwent surgery required a reintervention. CONCLUSIONS AND RELEVANCE: Among intermediate-risk patients with symptomatic severe aortic stenosis, major clinical outcomes at 5 years were similar for TAVR and surgery. TAVR was associated with superior hemodynamic valve performance but also with more paravalvular leak and valve reinterventions.
引用
- Van Mieghem NM, Deeb GM, Søndergaard L, et al. Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial. JAMA Cardiol. 2022. PMID: 36001335. doi:10.1001/jamacardio.2022.2695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。